InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.195 -0.055 (-22%)+
Announcement
Release
14 Sep 2026 8:39AM
Price at Release
$0.250
Full Release
download
Summary
Dimerix Limited announced that the Mexican Institute of Industrial Property granted a composition of matter patent in Mexico for DMX-652, its recently acquired first- and best-in-class USP30 inhibitor, strengthening the company’s global intellectual property position and commercialisation strategy for the asset. The patent, titled "N-cyanopyrrolidines with activity as USP30 inhibitors" and issued as patent number 438406, protects DMX-652 until 3 June 2041. Dimerix said the grant complements a recently granted US composition of matter patent and is significant given Mexico’s pharmaceutical market exceeds US$15 billion and is the second largest in Latin America. DMX-652 is a Phase 2-ready oral, once-daily small molecule being developed to prevent kidney injury and promote mitophagy by supporting removal of damaged mitochondria, with the initial clinical focus on acute kidney injury associated with cardiac surgery. The company noted there are currently no approved therapies for acute kidney injury, that the acquired package includes an open US IND, FDA-cleared Phase 2 protocol, GMP drug supply and manufacturing know-how, and that preparations are underway for the Phase 2 trial, underscoring the patent’s role in enhancing the long-term value and commercial attractiveness of DMX-652.
Key Points
  • Dimerix announced a Mexican composition of matter patent grant for DMX-652.
  • The patent was granted by the Mexican Institute of Industrial Property.
  • The patent is titled "N-cyanopyrrolidines with activity as USP30 inhibitors".
  • The Mexican patent number is 438406.
  • The patent provides protection for DMX-652 until 3 June 2041.
  • Dimerix said the grant strengthens its global intellectual property portfolio for DMX-652.
  • The company said the patent complements a recently granted US composition of matter patent.
  • Mexico’s pharmaceutical market was described as exceeding US$15 billion and being Latin America’s second largest.
  • DMX-652 is described as a first- and best-in-class USP30 inhibitor.
  • DMX-652 is being developed to prevent kidney injury and promote mitophagy.
  • The initial indication is acute kidney injury associated with cardiac surgery.
  • Preparations are underway for a Phase 2 clinical trial for DMX-652.
  • Dimerix said there are no approved therapies for acute kidney injury.
  • The DMX-652 acquisition included an open IND in the US and an FDA-cleared Phase 2 protocol.
  • The acquisition also included GMP drug product and manufacturing methodology.
  • Dimerix stated the patent improves the commercial attractiveness and long-term value of DMX-652.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.